New FDA draft guidance on charging for investigational drugs in clinical trials and expanded access situations provides answers to three new questions and additional guidance for eight questions contained in 2016 guidance. The draft guidance provides guidance to sponsors, researchers, physicians, institutional review boards (IRBs) and patients about the FDA’s regulations on c... Read More